Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection
- PMID: 19189905
- DOI: 10.7326/0003-4819-150-3-200902030-00005
Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection
Abstract
Background: Different immunochemical fecal occult blood tests (FOBTs) have been proposed for noninvasive colorectal cancer screening. Large-scale, colonoscopy-based screening studies that allow evaluation of these tests for the detection of precursor lesions are scarce.
Objective: To determine and compare performance characteristics of 6 qualitative immunochemical FOBTs for identifying colorectal adenomas among adults who attended screening colonoscopy examinations.
Design: Prospective screening study from January 2006 to December 2007.
Setting: 20 gastroenterology practices in Germany that did screening colonoscopy.
Patients: 1319 participants at average risk for colorectal neoplasia who were undergoing screening colonoscopy (mean age, 63 years; 50% men).
Measurements: 6 different qualitative immunochemical FOBTs were done with stool samples collected before bowel preparation for colonoscopy. Performance characteristics (sensitivity, specificity, predictive values, and likelihood ratios) of tests were measured by comparing test results with findings on colonoscopy. Technicians who read the tests were blinded to colonoscopy results, and colonoscopists were blinded to FOBT results.
Results: Overall, 405 participants (31%) had an adenoma and 130 participants (10%) had an advanced adenoma. Performance characteristics varied widely among tests. For the 2 best-performing tests (immoCARE-C [CAREdiagnostica, Voerde, Germany] and FOB advanced [ulti med, Ahrensburg, Germany]), the sensitivity for detection of advanced adenomas was 25% (95% CI, 18% to 34%) and 27% (CI, 20% to 35%), respectively; specificity was 97% (CI, 95% to 98%) and 93% (CI, 91% to 95%); and the positive likelihood ratio was 3.5 (CI, 2.2 to 5.4) and 2.5 (CI, 1.9 to 3.5).
Limitation: The study differed from real-life conditions in that stool samples were not directly dissolved in a buffer-filled vial; instead, a small container was used and stool was frozen before testing.
Conclusion: Qualitative immunochemical FOBTs could be an option for future colorectal cancer screening because they showed better performance characteristics for precursor lesions than guaiac-based FOBTs and are practical for mass screening. However, given the large differences in diagnostic performance among tests, careful evaluation of the different test variants is important.
Funding: The German Research Foundation (Deutsche Forschungsgemeinschaft) within the framework of a PhD program (Graduiertenkolleg 793).
Summary for patients in
-
Summaries for patients. Immunochemical fecal occult blood tests.Ann Intern Med. 2009 Feb 3;150(3):I34. doi: 10.7326/0003-4819-150-3-200902030-00002. Ann Intern Med. 2009. PMID: 19189901 No abstract available.
Similar articles
-
Quantitative immunochemical fecal occult blood testing for colorectal adenoma detection: evaluation in the target population of screening and comparison with qualitative tests.Am J Gastroenterol. 2010 Mar;105(3):682-90. doi: 10.1038/ajg.2009.668. Epub 2009 Dec 1. Am J Gastroenterol. 2010. PMID: 19953091
-
A quantitative immunochemical fecal occult blood test for colorectal neoplasia.Ann Intern Med. 2007 Feb 20;146(4):244-55. doi: 10.7326/0003-4819-146-4-200702200-00003. Ann Intern Med. 2007. PMID: 17310048
-
Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population.Gastroenterology. 2008 Jul;135(1):82-90. doi: 10.1053/j.gastro.2008.03.040. Epub 2008 Mar 25. Gastroenterology. 2008. PMID: 18482589 Clinical Trial.
-
A Comparison of the Cost-Effectiveness of Fecal Occult Blood Tests with Different Test Characteristics in the Context of Annual Screening in the Medicare Population [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2003 Aug 9. Rockville (MD): Agency for Healthcare Research and Quality (US); 2003 Aug 9. PMID: 25905156 Free Books & Documents. Review.
-
Colorectal Cancer Screening With Traditional and New-generation Fecal Immunochemical Tests: A Critical Review of Fecal Occult Blood Tests.Anticancer Res. 2020 Feb;40(2):575-581. doi: 10.21873/anticanres.13987. Anticancer Res. 2020. PMID: 32014898 Review.
Cited by
-
The Effectiveness of a Physician-Only and Physician-Patient Intervention on Colorectal Cancer Screening Discussions Between Providers and African American and Latino Patients.J Gen Intern Med. 2015 Dec;30(12):1780-7. doi: 10.1007/s11606-015-3381-8. Epub 2015 May 19. J Gen Intern Med. 2015. PMID: 25986137 Free PMC article. Clinical Trial.
-
Correlation of Repeat Measurements of 27 Candidate Protein Markers for Colorectal Cancer Screening Taken Three Years and Multiple Freeze-Thaw Cycles Apart.Life (Basel). 2022 Mar 2;12(3):359. doi: 10.3390/life12030359. Life (Basel). 2022. PMID: 35330110 Free PMC article.
-
Gut Microbiota in Colorectal Cancer: Biological Role and Therapeutic Opportunities.Cancers (Basel). 2023 Jan 30;15(3):866. doi: 10.3390/cancers15030866. Cancers (Basel). 2023. PMID: 36765824 Free PMC article. Review.
-
Potential Modifiers and Different Cut-offs in Diagnostic Accuracy of Fecal Immunochemical Test in Detecting Advanced Colon Neoplasia: A Diagnostic Test Accuracy Meta-analysis.Middle East J Dig Dis. 2022 Oct;14(4):382-395. doi: 10.34172/mejdd.2022.299. Epub 2022 Oct 30. Middle East J Dig Dis. 2022. PMID: 37547494 Free PMC article.
-
Genetic Risk Score Is Associated With Prevalence of Advanced Neoplasms in a Colorectal Cancer Screening Population.Gastroenterology. 2018 Jul;155(1):88-98.e10. doi: 10.1053/j.gastro.2018.03.030. Epub 2018 Mar 21. Gastroenterology. 2018. PMID: 29574091 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical